space city news

First commercial space station on the planet to be built in Houston

The world's first commercial space station will be built in Space City. Image via axiomspace.com

Houston's Spaceport will be the place where the world's first commercial space station will be built, according to Mayor Sylvester Turner.

The announcement was made during a December 22 briefing, where Turner announced the partnership between the Houston Spaceport and Axiom Space.

"Our great city is known for taking on humankind's boldest challenges," Turner said. "In 2021, the Houston Spaceport will be the first headquarters for Axiom Space, a privately funded space enterprise."

According to Turner, Axiom Space will construct a 14-acre headquarters. The headquarters "will be the world's first free-flying internationally available private space station that will serve as humanity's central hub for research, manufacturing, and commerce," Turner said.

The partnership is expected to bring more than 1,000 high-paying jobs, from engineers to scientists, mathematicians, and machinists.

"This opportunity will energize our workforce, engage our communities, and dare our young students to look up, wonder, and dream," Turner said.

Houston Spaceport is the country's 10th commercially licensed Spaceport and located at Ellington Airport.

The Houston area has played a key role for decades in the future of aerospace aviation. The Federal Aviation Administration granted formal approval for the city of Houston to making Ellington a launch site for reusable launch vehicles in 2015.

---

For more on this story, visit our news partner ABC13.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News